- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01263470
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan
A Phase 2, Double-blind, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Determine the Efficacy and Safety of SYR-322 in Subjects With Type 2 Diabetes in Japan
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Both insulin hyposecretion and insulin-resistance are considered to be involved in the development of type 2 diabetes mellitus.
Takeda is developing SYR-322 (alogliptin) for the improvement of glycemic control in patients with type 2 diabetes mellitus. Alogliptin is an inhibitor of the dipeptidyl peptidase IV (DPP-IV) enzyme. DPP-IV is thought to be primarily responsible for the degradation of 2 peptide hormones released in response to nutrient ingestion. It is expected that inhibition of DPP-IV will improve glycemic control in patients with type 2 diabetes.
To evaluate the long-term safety and efficacy of alogliptin, participants in the present study could enter a long-term extension study SYR-322/OCT-001 (NCT01263496) that was planned separately.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Okayama, Japan, 701-0192
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- A glycosylated hemoglobin (HbA1c) value of 6.5% or more and below 10.0% 4 weeks after the start of screening(Week -4).
- A HbA1c differences within 10.0%* (*rounded off to the first decimal point) at the start of screening (Week -8) and 4 weeks after the start of screening (Week -4) from the HbA1c value at the start of screening.
- Was receiving a specific diet therapy and an exercise therapy (if any) for the last 4 weeks or longer before the start of screening (Week -8).
Exclusion Criteria:
- Received any antidiabetic drug within the last 4 weeks before the start of screening (Week -8) or during screening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
|
Experimental: Alogliptin 12.5 mg QD
|
Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
Other Names:
Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
Other Names:
Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
Other Names:
Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
Other Names:
|
Experimental: Alogliptin 25 mg QD
|
Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
Other Names:
Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
Other Names:
Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
Other Names:
Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
Other Names:
|
Experimental: Alogliptin 50 mg QD
|
Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
Other Names:
Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
Other Names:
Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
Other Names:
Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
Other Names:
|
Experimental: Alogliptin 6.25 mg QD
|
Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
Other Names:
Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
Other Names:
Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
Other Names:
Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
Other Names:
|
Active Comparator: Voglibose 0.2 mg TID
|
Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Glycosylated Hemoglobin (Week 12).
Time Frame: Baseline and Week 12.
|
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 12 or final visit and glycosylated hemoglobin collected at baseline.
|
Baseline and Week 12.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Glycosylated Hemoglobin (Week 8).
Time Frame: Baseline and Week 8.
|
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 8 and glycosylated hemoglobin collected at baseline.
|
Baseline and Week 8.
|
Change From Baseline in Fasting Plasma Glucose (Week 8).
Time Frame: Baseline and Week 8.
|
The change between the value of fasting plasma glucose collected at week 8 and fasting plasma glucose collected at baseline.
|
Baseline and Week 8.
|
Change From Baseline in Fasting C-peptide (Week 8).
Time Frame: Baseline and Week 8.
|
The change between the value of fasting C-peptide collected at week 8 and fasting C-peptide collected at baseline.
|
Baseline and Week 8.
|
Change From Baseline in Glycosylated Hemoglobin (Week 2).
Time Frame: Baseline and Week 2.
|
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 2 and glycosylated hemoglobin collected at baseline.
|
Baseline and Week 2.
|
Change From Baseline in Glycosylated Hemoglobin (Week 4).
Time Frame: Baseline and Week 4.
|
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 4 and glycosylated hemoglobin collected at baseline.
|
Baseline and Week 4.
|
Change From Baseline in Fasting Plasma Glucose (Week 2).
Time Frame: Baseline and Week 2
|
The change between the value of fasting plasma glucose collected at week 2 and fasting plasma glucose collected at baseline.
|
Baseline and Week 2
|
Change From Baseline in Fasting Plasma Glucose (Week 4).
Time Frame: Baseline and Week 4.
|
The change between the value of fasting plasma glucose collected at week 4 and fasting plasma glucose collected at baseline.
|
Baseline and Week 4.
|
Change From Baseline in Fasting Plasma Glucose (Week 12).
Time Frame: Baseline and Week 12.
|
The change between the value of fasting plasma glucose collected at week 12 or final visit and fasting plasma glucose collected at baseline.
|
Baseline and Week 12.
|
Change From Baseline in Fasting C-peptide (Week 2).
Time Frame: Baseline and Week 2.
|
The change between the value of fasting C-peptide collected at week 2 and fasting C-peptide collected at baseline.
|
Baseline and Week 2.
|
Change From Baseline in Fasting C-peptide (Week 4).
Time Frame: Baseline and Week 4.
|
The change between the value of fasting C-peptide collected at week 4 and fasting C-peptide collected at baseline.
|
Baseline and Week 4.
|
Change From Baseline in Fasting C-peptide (Week 12).
Time Frame: Baseline and Week 12.
|
The change between the value of fasting C-peptide collected at week 12 or final visit and fasting C-peptide collected at baseline.
|
Baseline and Week 12.
|
Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing (2-hr Postprandial Value).
Time Frame: Baseline and Week 12.
|
The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline.
Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.
|
Baseline and Week 12.
|
Change From Baseline in Blood Glucose Measured by Meal Tolerance Testing - Area Under the Curve at 2 Hours (AUC (0-2)).
Time Frame: Baseline and Week 12.
|
The change between the value of blood glucose collected at week 12 or final visit and blood glucose collected at baseline.
Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and at 2 hours after the start of the meal.
|
Baseline and Week 12.
|
Change From Baseline in Insulin Measured by Meal Tolerance Testing - Area Under the Curve at 2 Hours (AUC(0-2)).
Time Frame: Baseline and Week 12
|
The change between the value of insulin collected at week 12 or final visit and insulin collected at baseline as measured by the meal tolerance test.
Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.
|
Baseline and Week 12
|
Change From Baseline in C-peptide Measured by Meal Tolerance Testing (AUC(0-2).
Time Frame: Baseline and Week 12.
|
The change between the value of C-peptide collected at week 12 or final visit and C-peptide collected at baseline as measured by the meal tolerance test.
Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.
|
Baseline and Week 12.
|
Change From Baseline in Glucagon Measured by Meal Tolerance Testing (AUC (0-2)).
Time Frame: Baseline and Week 12
|
The change between the value of glucagons collected at week 12 or final visit and glucagons collected at baseline.
Meal tolerance test measures blood glucose, insulin, C-peptide and glucagon through blood samples drawn before a meal and 2 hours after the start of the meal.
|
Baseline and Week 12
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Professor, Department of Medicine, Kawasaki Medical School
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Dipeptidyl-Peptidase IV Inhibitors
- Glycoside Hydrolase Inhibitors
- Alogliptin
- Voglibose
Other Study ID Numbers
- SYR-322/CCT-001
- U1111-1118-3752 (Registry Identifier: WHO)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
AstraZenecaNot yet recruiting
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States